Clinical Pharmacokinetics of Pancuronium Bromide
Overview
Authors
Affiliations
Plasma concentrations of pancuronium bromide have been studied in seven surgical patients following a 6 mg intravenous bolus injection of the drug for neuromuscular blockade. Concurrently, evoked muscle twitch response was monitored for each patient as a measure of the pharmacodynamic effect of the drug. The plasma decay curve for pancuronium was found to be biphasic and after rigorous statistical analysis the data were interpreted according to a 2-compartment open model. The half-life of the beta-phase varied between 89.5 and 161.5 min. The apparent volume of distribution of the central compartment ranged from 62.9 to145.5 ml/kg and the plasma clearance from 57.6 to 187.3 ml/min. At the first sign of recovery from neuro-muscular blockade the mean pancuronium plasma level was found to be 0.218 mcg/ml. The mean duration of action as measured from time of onset of paralysis to 20% recovery was 83.4 min with the plasma level at 20% being 0.169 mcg/ml corresponding to 45.4% of dose remaining to be eliminated from the body.
Beaufort T, Proost J, Kuizenga K, Houwertjes M, Kleef U, Wierda J J Pharmacokinet Biopharm. 1999; 27(2):173-90.
PMID: 10567954 DOI: 10.1023/a:1020653922866.
Anaesthesia in the elderly. Special considerations.
Jones A, Hunter J Drugs Aging. 1996; 9(5):319-31.
PMID: 8922559 DOI: 10.2165/00002512-199609050-00003.
Clinical pharmacokinetics of alcuronium chloride in man.
Walker J, SHANKS C, Triggs E Eur J Clin Pharmacol. 1980; 17(6):449-57.
PMID: 7398736 DOI: 10.1007/BF00570163.
Clinical pharmacokinetics of the non-depolarising muscle relaxants.
Ramzan M, Somogyi A, Walker J, SHANKS C, Triggs E Clin Pharmacokinet. 1981; 6(1):25-60.
PMID: 7018787 DOI: 10.2165/00003088-198106010-00002.
An analytical pharmacodynamic model for nondepolarizing neuromuscular blocking agents.
Dhollander A, Delcroix C J Pharmacokinet Biopharm. 1981; 9(1):27-40.
PMID: 6453216 DOI: 10.1007/BF01059341.